Short Interest in Seer, Inc. (NASDAQ:SEER) Decreases By 82.1%

Seer, Inc. (NASDAQ:SEER) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 279,535 shares, a decrease of 82.1% from the December 15th total of 1,563,815 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 212,773 shares, the short-interest ratio is presently 1.3 days. Based on an average daily trading volume, of 212,773 shares, the short-interest ratio is presently 1.3 days. Approximately 0.6% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of research analysts have commented on SEER shares. Wall Street Zen raised Seer to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Seer has a consensus rating of “Sell”.

Insider Transactions at Seer

In other news, CEO Omid Farokhzad sold 33,838 shares of the stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $1.97, for a total transaction of $66,660.86. Following the completion of the sale, the chief executive officer directly owned 1,238,230 shares in the company, valued at approximately $2,439,313.10. This represents a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.28% of the stock is currently owned by company insiders.

Institutional Trading of Seer

Hedge funds have recently modified their holdings of the business. Occudo Quantitative Strategies LP purchased a new stake in shares of Seer in the 2nd quarter worth about $25,000. Quadrature Capital Ltd bought a new stake in Seer during the second quarter worth about $47,000. Corient Private Wealth LLC grew its holdings in Seer by 46.3% in the second quarter. Corient Private Wealth LLC now owns 63,200 shares of the company’s stock worth $135,000 after purchasing an additional 20,000 shares during the period. Shay Capital LLC increased its stake in shares of Seer by 17.7% during the third quarter. Shay Capital LLC now owns 73,571 shares of the company’s stock valued at $160,000 after purchasing an additional 11,073 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Seer during the second quarter valued at approximately $172,000. Institutional investors own 75.20% of the company’s stock.

Seer Stock Performance

Seer stock opened at $1.95 on Tuesday. The stock’s 50 day simple moving average is $1.92 and its two-hundred day simple moving average is $2.07. The stock has a market cap of $108.79 million, a price-to-earnings ratio of -1.43 and a beta of 1.60. Seer has a fifty-two week low of $1.62 and a fifty-two week high of $2.44.

Seer (NASDAQ:SEER) last announced its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. The firm had revenue of $4.12 million during the quarter, compared to analyst estimates of $4.00 million. Seer had a negative return on equity of 25.88% and a negative net margin of 484.51%. On average, analysts predict that Seer will post -1.42 earnings per share for the current year.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.